The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Group B Streptococcus Infection Treatment Market Over The 2026–2030 Period?
The group b streptococcus infection treatment market has shown significant expansion in recent years. This market is anticipated to expand from $1.26 billion in 2025 to $1.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. Factors contributing to its historical growth include increased understanding of neonatal infections, the broadening of prenatal care programs, the extensive use of beta-lactam antibiotics, the rise in hospital-based screening protocols, and the provision of microbiological testing services.
The group b streptococcus infection treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $1.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. This projected growth is driven by factors such as the accelerated development of GBS vaccines, increased integration of point-of-care diagnostics, a heightened focus on managing antimicrobial resistance, the broadening of molecular testing infrastructure, and a stronger emphasis on preventative maternal healthcare. Key trends influencing this period encompass the widespread adoption of rapid molecular diagnostic testing, a greater emphasis on prenatal GBS screening initiatives, the increased implementation of antibiotic stewardship protocols, the expansion of therapeutic pipelines aimed at GBS prevention, and improved surveillance of maternal and neonatal health outcomes.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33144&type=smp
What Primary Drivers Are Shaping The Development Of The Group B Streptococcus Infection Treatment Market?
The escalating healthcare expenditure is projected to stimulate the expansion of the group B streptococcus infection treatment market moving forward. Healthcare expenditure signifies the entire financial resources dedicated to medical services, preventative care, medications, infrastructure, and associated health endeavors to preserve or improve the well-being of the population. This increase in healthcare spending is attributed to the growing prevalence of chronic and infectious diseases, which in turn fosters a sustained requirement for long-term treatment, cutting-edge therapies, and continuous medical attention. The expansion of healthcare expenditure strengthens the group B Streptococcus infection treatment by boosting investments in prenatal screening, clinical infrastructure, and vaccine research, collectively enhancing early detection, prevention, and effective management of GBS infections in mothers and newborns. For instance, in April 2025, according to the Office for National Statistics, a UK-based government organization, overall healthcare spending rose by 6.5% from 2023 to 2024, indicating an acceleration compared with the 6.3% growth recorded in 2023. Therefore, the rising healthcare expenditure is a primary driver for the growth of the group B streptococcus infection treatment market.
How Is The Group B Streptococcus Infection Treatment Market Segmented Across Key Categories?
The group b streptococcus infection treatment market covered in this report is segmented –
1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies
2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies
3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application
4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population
5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings
Subsegments:
1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics
2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy
3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies
Which Upcoming Trends Are Expected To Influence The Group B Streptococcus Infection Treatment Market?
Leading companies operating within the group B streptococcus infection treatment market are concentrating on the creation of innovative products, such as polysaccharide conjugate vaccines, with the aim of reducing asymptomatic bacterial carriage. These polysaccharide conjugate vaccines are a type of immunization where bacterial surface sugars are chemically joined to a carrier protein. This combination is designed to enhance immune system recognition and generate a robust, long-lasting protective response, especially beneficial for infants and young children. For instance, in September 2023, Omniose, a US-based biotechnology company, announced it had been awarded a grant of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health, specifically to support the development of a Group B Streptococcus (GBS) vaccine. A key differentiating aspect of this vaccine is its ambition to achieve high efficacy through a significantly simplified manufacturing method. Omniose’s platform employs synthetic biology and a unique one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, thereby bypassing conventional chemical conjugation steps. This particular process guarantees the preservation of 100% of sialic acid residues on each capsular polysaccharide, a factor that has been demonstrated as critical for inducing potent functional antibody responses against specific GBS serotypes.
Who Are The Top Companies Competing In The Group B Streptococcus Infection Treatment Market?
Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.
Read the full group b streptococcus infection treatment market report here:
Which Region Is Expected To Experience The Fastest Growth In The Group B Streptococcus Infection Treatment Market?
North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the group b streptococcus infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Group B Streptococcus Infection Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33144&type=smp
Browse Through More Reports Similar to the Global Group B Streptococcus Infection Treatment Market 2026, By The Business Research Company
Strep Throat Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/strep-throat-treatment-global-market-report
Antibacterial Products Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report
Hospital Acquired Infection Control Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model